nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—PTGS2—skin cancer	0.514	1	CbGaD
Nabumetone—CYP1A2—Imiquimod—skin cancer	0.134	0.452	CbGbCtD
Nabumetone—CYP1A2—Vemurafenib—skin cancer	0.0735	0.247	CbGbCtD
Nabumetone—CYP1A2—Dacarbazine—skin cancer	0.0563	0.19	CbGbCtD
Nabumetone—CYP1A2—Fluorouracil—skin cancer	0.033	0.111	CbGbCtD
Nabumetone—MPO—endothelium—skin cancer	0.0034	0.0824	CbGeAlD
Nabumetone—PTGS2—leg—skin cancer	0.00333	0.0808	CbGeAlD
Nabumetone—MPO—blood vessel—skin cancer	0.00313	0.076	CbGeAlD
Nabumetone—PTGS2—hindlimb—skin cancer	0.00298	0.0722	CbGeAlD
Nabumetone—PTGS2—appendage—skin cancer	0.00255	0.0619	CbGeAlD
Nabumetone—PTGS2—skin epidermis—skin cancer	0.00212	0.0515	CbGeAlD
Nabumetone—PTGS1—endothelium—skin cancer	0.00161	0.0391	CbGeAlD
Nabumetone—MPO—connective tissue—skin cancer	0.00161	0.039	CbGeAlD
Nabumetone—PTGS2—endothelium—skin cancer	0.00154	0.0374	CbGeAlD
Nabumetone—MPO—epithelium—skin cancer	0.00153	0.037	CbGeAlD
Nabumetone—PTGS1—blood vessel—skin cancer	0.00149	0.0361	CbGeAlD
Nabumetone—MPO—skin of body—skin cancer	0.00145	0.0352	CbGeAlD
Nabumetone—PTGS2—blood vessel—skin cancer	0.00142	0.0345	CbGeAlD
Nabumetone—CYP1A2—nipple—skin cancer	0.00124	0.0301	CbGeAlD
Nabumetone—MPO—lymphoid tissue—skin cancer	0.00117	0.0285	CbGeAlD
Nabumetone—PTGS1—nipple—skin cancer	0.00107	0.0261	CbGeAlD
Nabumetone—MPO—head—skin cancer	0.000947	0.023	CbGeAlD
Nabumetone—PTGS1—connective tissue—skin cancer	0.000762	0.0185	CbGeAlD
Nabumetone—PTGS2—connective tissue—skin cancer	0.000729	0.0177	CbGeAlD
Nabumetone—PTGS1—epithelium—skin cancer	0.000724	0.0176	CbGeAlD
Nabumetone—PTGS2—epithelium—skin cancer	0.000692	0.0168	CbGeAlD
Nabumetone—PTGS1—skin of body—skin cancer	0.000688	0.0167	CbGeAlD
Nabumetone—MPO—lymph node—skin cancer	0.000663	0.0161	CbGeAlD
Nabumetone—PTGS2—skin of body—skin cancer	0.000658	0.016	CbGeAlD
Nabumetone—PTGS1—mammalian vulva—skin cancer	0.000628	0.0152	CbGeAlD
Nabumetone—PTGS1—female reproductive system—skin cancer	0.000538	0.013	CbGeAlD
Nabumetone—PTGS2—lymphoid tissue—skin cancer	0.000533	0.0129	CbGeAlD
Nabumetone—PTGS2—female reproductive system—skin cancer	0.000514	0.0125	CbGeAlD
Nabumetone—Fatigue—Vemurafenib—skin cancer	0.00047	0.00319	CcSEcCtD
Nabumetone—Haemoglobin—Bleomycin—skin cancer	0.000467	0.00317	CcSEcCtD
Nabumetone—Constipation—Vemurafenib—skin cancer	0.000466	0.00316	CcSEcCtD
Nabumetone—Oedema—Imiquimod—skin cancer	0.000465	0.00315	CcSEcCtD
Nabumetone—Haemorrhage—Bleomycin—skin cancer	0.000465	0.00315	CcSEcCtD
Nabumetone—Dysuria—Temozolomide—skin cancer	0.000458	0.00311	CcSEcCtD
Nabumetone—Shock—Imiquimod—skin cancer	0.000458	0.0031	CcSEcCtD
Nabumetone—Dysphagia—Fluorouracil—skin cancer	0.000452	0.00306	CcSEcCtD
Nabumetone—Erectile dysfunction—Temozolomide—skin cancer	0.000451	0.00306	CcSEcCtD
Nabumetone—Agranulocytosis—Dactinomycin—skin cancer	0.000451	0.00305	CcSEcCtD
Nabumetone—Hyperhidrosis—Imiquimod—skin cancer	0.00045	0.00305	CcSEcCtD
Nabumetone—PTGS1—head—skin cancer	0.000449	0.0109	CbGeAlD
Nabumetone—Photosensitivity reaction—Temozolomide—skin cancer	0.000447	0.00303	CcSEcCtD
Nabumetone—Weight increased—Temozolomide—skin cancer	0.000446	0.00302	CcSEcCtD
Nabumetone—Weight decreased—Temozolomide—skin cancer	0.000443	0.003	CcSEcCtD
Nabumetone—Anorexia—Imiquimod—skin cancer	0.000443	0.003	CcSEcCtD
Nabumetone—Hyperglycaemia—Temozolomide—skin cancer	0.000442	0.003	CcSEcCtD
Nabumetone—Angina pectoris—Fluorouracil—skin cancer	0.00044	0.00298	CcSEcCtD
Nabumetone—Pneumonia—Temozolomide—skin cancer	0.00044	0.00298	CcSEcCtD
Nabumetone—Depression—Temozolomide—skin cancer	0.000436	0.00295	CcSEcCtD
Nabumetone—Thrombophlebitis—Docetaxel—skin cancer	0.000436	0.00295	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000433	0.00294	CcSEcCtD
Nabumetone—Body temperature increased—Vemurafenib—skin cancer	0.000431	0.00292	CcSEcCtD
Nabumetone—PTGS2—head—skin cancer	0.000429	0.0104	CbGeAlD
Nabumetone—Stomatitis—Temozolomide—skin cancer	0.000426	0.00289	CcSEcCtD
Nabumetone—Insomnia—Imiquimod—skin cancer	0.000421	0.00285	CcSEcCtD
Nabumetone—Hepatic failure—Docetaxel—skin cancer	0.00042	0.00284	CcSEcCtD
Nabumetone—Paraesthesia—Imiquimod—skin cancer	0.000418	0.00283	CcSEcCtD
Nabumetone—Chills—Bleomycin—skin cancer	0.000417	0.00283	CcSEcCtD
Nabumetone—Dyspnoea—Imiquimod—skin cancer	0.000415	0.00281	CcSEcCtD
Nabumetone—Somnolence—Imiquimod—skin cancer	0.000413	0.0028	CcSEcCtD
Nabumetone—Photosensitivity reaction—Fluorouracil—skin cancer	0.000412	0.00279	CcSEcCtD
Nabumetone—Alopecia—Bleomycin—skin cancer	0.000411	0.00278	CcSEcCtD
Nabumetone—Erythema multiforme—Dactinomycin—skin cancer	0.00041	0.00278	CcSEcCtD
Nabumetone—Dyspepsia—Imiquimod—skin cancer	0.000409	0.00277	CcSEcCtD
Nabumetone—Pneumonia—Fluorouracil—skin cancer	0.000405	0.00274	CcSEcCtD
Nabumetone—Decreased appetite—Imiquimod—skin cancer	0.000404	0.00274	CcSEcCtD
Nabumetone—Hypersensitivity—Vemurafenib—skin cancer	0.000402	0.00272	CcSEcCtD
Nabumetone—Fatigue—Imiquimod—skin cancer	0.000401	0.00272	CcSEcCtD
Nabumetone—Acute coronary syndrome—Fluorouracil—skin cancer	0.000397	0.00269	CcSEcCtD
Nabumetone—Myocardial infarction—Fluorouracil—skin cancer	0.000395	0.00267	CcSEcCtD
Nabumetone—Dermatitis bullous—Docetaxel—skin cancer	0.000395	0.00267	CcSEcCtD
Nabumetone—Haemoglobin—Temozolomide—skin cancer	0.000394	0.00267	CcSEcCtD
Nabumetone—Stomatitis—Fluorouracil—skin cancer	0.000392	0.00266	CcSEcCtD
Nabumetone—Haemorrhage—Temozolomide—skin cancer	0.000392	0.00266	CcSEcCtD
Nabumetone—Asthenia—Vemurafenib—skin cancer	0.000391	0.00265	CcSEcCtD
Nabumetone—Chills—Dactinomycin—skin cancer	0.000389	0.00264	CcSEcCtD
Nabumetone—Pruritus—Vemurafenib—skin cancer	0.000386	0.00261	CcSEcCtD
Nabumetone—Alopecia—Dactinomycin—skin cancer	0.000383	0.0026	CcSEcCtD
Nabumetone—Feeling abnormal—Imiquimod—skin cancer	0.000383	0.0026	CcSEcCtD
Nabumetone—Gastrointestinal pain—Imiquimod—skin cancer	0.00038	0.00258	CcSEcCtD
Nabumetone—Visual impairment—Temozolomide—skin cancer	0.000378	0.00256	CcSEcCtD
Nabumetone—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000377	0.00256	CcSEcCtD
Nabumetone—Agranulocytosis—Fluorouracil—skin cancer	0.000376	0.00255	CcSEcCtD
Nabumetone—Ill-defined disorder—Bleomycin—skin cancer	0.000376	0.00254	CcSEcCtD
Nabumetone—Anaemia—Bleomycin—skin cancer	0.000374	0.00254	CcSEcCtD
Nabumetone—Diarrhoea—Vemurafenib—skin cancer	0.000373	0.00253	CcSEcCtD
Nabumetone—Erythema multiforme—Temozolomide—skin cancer	0.000371	0.00251	CcSEcCtD
Nabumetone—Urticaria—Imiquimod—skin cancer	0.000369	0.0025	CcSEcCtD
Nabumetone—Abdominal pain—Imiquimod—skin cancer	0.000368	0.00249	CcSEcCtD
Nabumetone—Body temperature increased—Imiquimod—skin cancer	0.000368	0.00249	CcSEcCtD
Nabumetone—Tinnitus—Temozolomide—skin cancer	0.000366	0.00248	CcSEcCtD
Nabumetone—Malaise—Bleomycin—skin cancer	0.000365	0.00247	CcSEcCtD
Nabumetone—Haemoglobin—Fluorouracil—skin cancer	0.000363	0.00246	CcSEcCtD
Nabumetone—Leukopenia—Bleomycin—skin cancer	0.000362	0.00246	CcSEcCtD
Nabumetone—Haemorrhage—Fluorouracil—skin cancer	0.000361	0.00245	CcSEcCtD
Nabumetone—Dizziness—Vemurafenib—skin cancer	0.000361	0.00244	CcSEcCtD
Nabumetone—Cough—Bleomycin—skin cancer	0.000353	0.00239	CcSEcCtD
Nabumetone—Chills—Temozolomide—skin cancer	0.000352	0.00238	CcSEcCtD
Nabumetone—Ill-defined disorder—Dactinomycin—skin cancer	0.00035	0.00237	CcSEcCtD
Nabumetone—Anaemia—Dactinomycin—skin cancer	0.000349	0.00236	CcSEcCtD
Nabumetone—Liver function test abnormal—Docetaxel—skin cancer	0.000348	0.00236	CcSEcCtD
Nabumetone—Vomiting—Vemurafenib—skin cancer	0.000347	0.00235	CcSEcCtD
Nabumetone—Alopecia—Temozolomide—skin cancer	0.000347	0.00235	CcSEcCtD
Nabumetone—Rash—Vemurafenib—skin cancer	0.000344	0.00233	CcSEcCtD
Nabumetone—Dermatitis—Vemurafenib—skin cancer	0.000344	0.00233	CcSEcCtD
Nabumetone—Hypersensitivity—Imiquimod—skin cancer	0.000343	0.00232	CcSEcCtD
Nabumetone—Headache—Vemurafenib—skin cancer	0.000342	0.00231	CcSEcCtD
Nabumetone—Discomfort—Bleomycin—skin cancer	0.000341	0.00231	CcSEcCtD
Nabumetone—Malaise—Dactinomycin—skin cancer	0.000341	0.00231	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.00034	0.0023	CcSEcCtD
Nabumetone—Leukopenia—Dactinomycin—skin cancer	0.000338	0.00229	CcSEcCtD
Nabumetone—Asthenia—Imiquimod—skin cancer	0.000334	0.00226	CcSEcCtD
Nabumetone—Confusional state—Bleomycin—skin cancer	0.000333	0.00226	CcSEcCtD
Nabumetone—Anaphylactic shock—Bleomycin—skin cancer	0.00033	0.00224	CcSEcCtD
Nabumetone—Oedema—Bleomycin—skin cancer	0.00033	0.00224	CcSEcCtD
Nabumetone—Pruritus—Imiquimod—skin cancer	0.000329	0.00223	CcSEcCtD
Nabumetone—Dysphagia—Docetaxel—skin cancer	0.000326	0.00221	CcSEcCtD
Nabumetone—Nausea—Vemurafenib—skin cancer	0.000324	0.00219	CcSEcCtD
Nabumetone—Thrombocytopenia—Bleomycin—skin cancer	0.000324	0.00219	CcSEcCtD
Nabumetone—Arrhythmia—Fluorouracil—skin cancer	0.000323	0.00219	CcSEcCtD
Nabumetone—Tremor—Temozolomide—skin cancer	0.00032	0.00217	CcSEcCtD
Nabumetone—Alopecia—Fluorouracil—skin cancer	0.000319	0.00216	CcSEcCtD
Nabumetone—Diarrhoea—Imiquimod—skin cancer	0.000318	0.00216	CcSEcCtD
Nabumetone—Discomfort—Dactinomycin—skin cancer	0.000318	0.00215	CcSEcCtD
Nabumetone—Angina pectoris—Docetaxel—skin cancer	0.000318	0.00215	CcSEcCtD
Nabumetone—Ill-defined disorder—Temozolomide—skin cancer	0.000317	0.00215	CcSEcCtD
Nabumetone—Anaemia—Temozolomide—skin cancer	0.000316	0.00214	CcSEcCtD
Nabumetone—Anorexia—Bleomycin—skin cancer	0.000315	0.00213	CcSEcCtD
Nabumetone—PTGS1—lymph node—skin cancer	0.000315	0.00763	CbGeAlD
Nabumetone—Agitation—Temozolomide—skin cancer	0.000314	0.00213	CcSEcCtD
Nabumetone—Angioedema—Temozolomide—skin cancer	0.000312	0.00211	CcSEcCtD
Nabumetone—Oedema—Dactinomycin—skin cancer	0.000308	0.00209	CcSEcCtD
Nabumetone—Malaise—Temozolomide—skin cancer	0.000308	0.00209	CcSEcCtD
Nabumetone—Dizziness—Imiquimod—skin cancer	0.000308	0.00208	CcSEcCtD
Nabumetone—Vertigo—Temozolomide—skin cancer	0.000307	0.00208	CcSEcCtD
Nabumetone—Leukopenia—Temozolomide—skin cancer	0.000306	0.00207	CcSEcCtD
Nabumetone—Palpitations—Temozolomide—skin cancer	0.000302	0.00204	CcSEcCtD
Nabumetone—Thrombocytopenia—Dactinomycin—skin cancer	0.000302	0.00204	CcSEcCtD
Nabumetone—PTGS2—lymph node—skin cancer	0.000301	0.00729	CbGeAlD
Nabumetone—Cough—Temozolomide—skin cancer	0.000298	0.00202	CcSEcCtD
Nabumetone—Paraesthesia—Bleomycin—skin cancer	0.000297	0.00201	CcSEcCtD
Nabumetone—Weight increased—Docetaxel—skin cancer	0.000297	0.00201	CcSEcCtD
Nabumetone—Vomiting—Imiquimod—skin cancer	0.000296	0.002	CcSEcCtD
Nabumetone—Weight decreased—Docetaxel—skin cancer	0.000295	0.002	CcSEcCtD
Nabumetone—Hypertension—Temozolomide—skin cancer	0.000295	0.002	CcSEcCtD
Nabumetone—Dyspnoea—Bleomycin—skin cancer	0.000295	0.002	CcSEcCtD
Nabumetone—Anorexia—Dactinomycin—skin cancer	0.000294	0.00199	CcSEcCtD
Nabumetone—Rash—Imiquimod—skin cancer	0.000293	0.00199	CcSEcCtD
Nabumetone—Dermatitis—Imiquimod—skin cancer	0.000293	0.00198	CcSEcCtD
Nabumetone—Pneumonia—Docetaxel—skin cancer	0.000292	0.00198	CcSEcCtD
Nabumetone—Headache—Imiquimod—skin cancer	0.000291	0.00197	CcSEcCtD
Nabumetone—Anaemia—Fluorouracil—skin cancer	0.000291	0.00197	CcSEcCtD
Nabumetone—Anxiety—Temozolomide—skin cancer	0.00029	0.00196	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000288	0.00195	CcSEcCtD
Nabumetone—Discomfort—Temozolomide—skin cancer	0.000287	0.00195	CcSEcCtD
Nabumetone—Decreased appetite—Bleomycin—skin cancer	0.000287	0.00195	CcSEcCtD
Nabumetone—Acute coronary syndrome—Docetaxel—skin cancer	0.000286	0.00194	CcSEcCtD
Nabumetone—Renal failure—Docetaxel—skin cancer	0.000286	0.00194	CcSEcCtD
Nabumetone—Myocardial infarction—Docetaxel—skin cancer	0.000285	0.00193	CcSEcCtD
Nabumetone—Dry mouth—Temozolomide—skin cancer	0.000284	0.00193	CcSEcCtD
Nabumetone—Stomatitis—Docetaxel—skin cancer	0.000283	0.00192	CcSEcCtD
Nabumetone—Jaundice—Docetaxel—skin cancer	0.000283	0.00192	CcSEcCtD
Nabumetone—Leukopenia—Fluorouracil—skin cancer	0.000282	0.00191	CcSEcCtD
Nabumetone—Confusional state—Temozolomide—skin cancer	0.000281	0.0019	CcSEcCtD
Nabumetone—Anaphylactic shock—Temozolomide—skin cancer	0.000279	0.00189	CcSEcCtD
Nabumetone—Oedema—Temozolomide—skin cancer	0.000279	0.00189	CcSEcCtD
Nabumetone—Nausea—Imiquimod—skin cancer	0.000276	0.00187	CcSEcCtD
Nabumetone—Thrombocytopenia—Temozolomide—skin cancer	0.000273	0.00185	CcSEcCtD
Nabumetone—Feeling abnormal—Bleomycin—skin cancer	0.000272	0.00184	CcSEcCtD
Nabumetone—Agranulocytosis—Docetaxel—skin cancer	0.000271	0.00184	CcSEcCtD
Nabumetone—Hyperhidrosis—Temozolomide—skin cancer	0.000269	0.00183	CcSEcCtD
Nabumetone—Decreased appetite—Dactinomycin—skin cancer	0.000268	0.00181	CcSEcCtD
Nabumetone—Fatigue—Dactinomycin—skin cancer	0.000266	0.0018	CcSEcCtD
Nabumetone—Anorexia—Temozolomide—skin cancer	0.000266	0.0018	CcSEcCtD
Nabumetone—Discomfort—Fluorouracil—skin cancer	0.000265	0.00179	CcSEcCtD
Nabumetone—Urticaria—Bleomycin—skin cancer	0.000262	0.00178	CcSEcCtD
Nabumetone—Haemoglobin—Docetaxel—skin cancer	0.000262	0.00178	CcSEcCtD
Nabumetone—Body temperature increased—Bleomycin—skin cancer	0.000261	0.00177	CcSEcCtD
Nabumetone—Haemorrhage—Docetaxel—skin cancer	0.000261	0.00177	CcSEcCtD
Nabumetone—Confusional state—Fluorouracil—skin cancer	0.000259	0.00175	CcSEcCtD
Nabumetone—Oedema—Fluorouracil—skin cancer	0.000257	0.00174	CcSEcCtD
Nabumetone—Anaphylactic shock—Fluorouracil—skin cancer	0.000257	0.00174	CcSEcCtD
Nabumetone—Feeling abnormal—Dactinomycin—skin cancer	0.000254	0.00172	CcSEcCtD
Nabumetone—Insomnia—Temozolomide—skin cancer	0.000252	0.00171	CcSEcCtD
Nabumetone—Gastrointestinal pain—Dactinomycin—skin cancer	0.000252	0.00171	CcSEcCtD
Nabumetone—Thrombocytopenia—Fluorouracil—skin cancer	0.000251	0.0017	CcSEcCtD
Nabumetone—Visual impairment—Docetaxel—skin cancer	0.000251	0.0017	CcSEcCtD
Nabumetone—Paraesthesia—Temozolomide—skin cancer	0.00025	0.0017	CcSEcCtD
Nabumetone—Dyspnoea—Temozolomide—skin cancer	0.000248	0.00168	CcSEcCtD
Nabumetone—Somnolence—Temozolomide—skin cancer	0.000248	0.00168	CcSEcCtD
Nabumetone—Erythema multiforme—Docetaxel—skin cancer	0.000247	0.00167	CcSEcCtD
Nabumetone—Dyspepsia—Temozolomide—skin cancer	0.000245	0.00166	CcSEcCtD
Nabumetone—Anorexia—Fluorouracil—skin cancer	0.000245	0.00166	CcSEcCtD
Nabumetone—Abdominal pain—Dactinomycin—skin cancer	0.000244	0.00165	CcSEcCtD
Nabumetone—Body temperature increased—Dactinomycin—skin cancer	0.000244	0.00165	CcSEcCtD
Nabumetone—Hypersensitivity—Bleomycin—skin cancer	0.000243	0.00165	CcSEcCtD
Nabumetone—Decreased appetite—Temozolomide—skin cancer	0.000242	0.00164	CcSEcCtD
Nabumetone—Fatigue—Temozolomide—skin cancer	0.00024	0.00163	CcSEcCtD
Nabumetone—Constipation—Temozolomide—skin cancer	0.000238	0.00161	CcSEcCtD
Nabumetone—Asthenia—Bleomycin—skin cancer	0.000237	0.00161	CcSEcCtD
Nabumetone—Chills—Docetaxel—skin cancer	0.000234	0.00159	CcSEcCtD
Nabumetone—Pruritus—Bleomycin—skin cancer	0.000234	0.00158	CcSEcCtD
Nabumetone—Arrhythmia—Docetaxel—skin cancer	0.000233	0.00158	CcSEcCtD
Nabumetone—Insomnia—Fluorouracil—skin cancer	0.000232	0.00157	CcSEcCtD
Nabumetone—Paraesthesia—Fluorouracil—skin cancer	0.000231	0.00156	CcSEcCtD
Nabumetone—Alopecia—Docetaxel—skin cancer	0.000231	0.00156	CcSEcCtD
Nabumetone—Feeling abnormal—Temozolomide—skin cancer	0.00023	0.00156	CcSEcCtD
Nabumetone—Dyspnoea—Fluorouracil—skin cancer	0.000229	0.00155	CcSEcCtD
Nabumetone—Somnolence—Fluorouracil—skin cancer	0.000228	0.00155	CcSEcCtD
Nabumetone—Gastrointestinal pain—Temozolomide—skin cancer	0.000228	0.00154	CcSEcCtD
Nabumetone—Hypersensitivity—Dactinomycin—skin cancer	0.000227	0.00154	CcSEcCtD
Nabumetone—Dyspepsia—Fluorouracil—skin cancer	0.000226	0.00153	CcSEcCtD
Nabumetone—Decreased appetite—Fluorouracil—skin cancer	0.000223	0.00151	CcSEcCtD
Nabumetone—Urticaria—Temozolomide—skin cancer	0.000221	0.0015	CcSEcCtD
Nabumetone—Asthenia—Dactinomycin—skin cancer	0.000221	0.0015	CcSEcCtD
Nabumetone—Abdominal pain—Temozolomide—skin cancer	0.00022	0.00149	CcSEcCtD
Nabumetone—Body temperature increased—Temozolomide—skin cancer	0.00022	0.00149	CcSEcCtD
Nabumetone—Feeling abnormal—Fluorouracil—skin cancer	0.000212	0.00143	CcSEcCtD
Nabumetone—Diarrhoea—Dactinomycin—skin cancer	0.000211	0.00143	CcSEcCtD
Nabumetone—Vomiting—Bleomycin—skin cancer	0.00021	0.00142	CcSEcCtD
Nabumetone—Anaemia—Docetaxel—skin cancer	0.00021	0.00142	CcSEcCtD
Nabumetone—Rash—Bleomycin—skin cancer	0.000208	0.00141	CcSEcCtD
Nabumetone—Dermatitis—Bleomycin—skin cancer	0.000208	0.00141	CcSEcCtD
Nabumetone—Hypersensitivity—Temozolomide—skin cancer	0.000205	0.00139	CcSEcCtD
Nabumetone—Urticaria—Fluorouracil—skin cancer	0.000204	0.00138	CcSEcCtD
Nabumetone—Syncope—Docetaxel—skin cancer	0.000204	0.00138	CcSEcCtD
Nabumetone—Leukopenia—Docetaxel—skin cancer	0.000203	0.00138	CcSEcCtD
Nabumetone—Body temperature increased—Fluorouracil—skin cancer	0.000203	0.00138	CcSEcCtD
Nabumetone—Palpitations—Docetaxel—skin cancer	0.000201	0.00136	CcSEcCtD
Nabumetone—Asthenia—Temozolomide—skin cancer	0.0002	0.00135	CcSEcCtD
Nabumetone—Loss of consciousness—Docetaxel—skin cancer	0.0002	0.00135	CcSEcCtD
Nabumetone—Cough—Docetaxel—skin cancer	0.000198	0.00134	CcSEcCtD
Nabumetone—Pruritus—Temozolomide—skin cancer	0.000197	0.00134	CcSEcCtD
Nabumetone—Nausea—Bleomycin—skin cancer	0.000196	0.00133	CcSEcCtD
Nabumetone—Hypertension—Docetaxel—skin cancer	0.000196	0.00133	CcSEcCtD
Nabumetone—Vomiting—Dactinomycin—skin cancer	0.000196	0.00133	CcSEcCtD
Nabumetone—Rash—Dactinomycin—skin cancer	0.000194	0.00132	CcSEcCtD
Nabumetone—Diarrhoea—Temozolomide—skin cancer	0.000191	0.00129	CcSEcCtD
Nabumetone—Hypersensitivity—Fluorouracil—skin cancer	0.000189	0.00128	CcSEcCtD
Nabumetone—Dry mouth—Docetaxel—skin cancer	0.000189	0.00128	CcSEcCtD
Nabumetone—Confusional state—Docetaxel—skin cancer	0.000187	0.00127	CcSEcCtD
Nabumetone—Anaphylactic shock—Docetaxel—skin cancer	0.000185	0.00126	CcSEcCtD
Nabumetone—Oedema—Docetaxel—skin cancer	0.000185	0.00126	CcSEcCtD
Nabumetone—Dizziness—Temozolomide—skin cancer	0.000184	0.00125	CcSEcCtD
Nabumetone—Nausea—Dactinomycin—skin cancer	0.000183	0.00124	CcSEcCtD
Nabumetone—Shock—Docetaxel—skin cancer	0.000182	0.00124	CcSEcCtD
Nabumetone—Pruritus—Fluorouracil—skin cancer	0.000182	0.00123	CcSEcCtD
Nabumetone—Thrombocytopenia—Docetaxel—skin cancer	0.000181	0.00123	CcSEcCtD
Nabumetone—Vomiting—Temozolomide—skin cancer	0.000177	0.0012	CcSEcCtD
Nabumetone—Anorexia—Docetaxel—skin cancer	0.000177	0.0012	CcSEcCtD
Nabumetone—Rash—Temozolomide—skin cancer	0.000176	0.00119	CcSEcCtD
Nabumetone—Diarrhoea—Fluorouracil—skin cancer	0.000176	0.00119	CcSEcCtD
Nabumetone—Dermatitis—Temozolomide—skin cancer	0.000176	0.00119	CcSEcCtD
Nabumetone—Headache—Temozolomide—skin cancer	0.000175	0.00118	CcSEcCtD
Nabumetone—Dizziness—Fluorouracil—skin cancer	0.00017	0.00115	CcSEcCtD
Nabumetone—Insomnia—Docetaxel—skin cancer	0.000168	0.00114	CcSEcCtD
Nabumetone—Paraesthesia—Docetaxel—skin cancer	0.000166	0.00113	CcSEcCtD
Nabumetone—Nausea—Temozolomide—skin cancer	0.000166	0.00112	CcSEcCtD
Nabumetone—Dyspnoea—Docetaxel—skin cancer	0.000165	0.00112	CcSEcCtD
Nabumetone—Somnolence—Docetaxel—skin cancer	0.000165	0.00112	CcSEcCtD
Nabumetone—Vomiting—Fluorouracil—skin cancer	0.000163	0.00111	CcSEcCtD
Nabumetone—Dyspepsia—Docetaxel—skin cancer	0.000163	0.00111	CcSEcCtD
Nabumetone—Rash—Fluorouracil—skin cancer	0.000162	0.0011	CcSEcCtD
Nabumetone—Dermatitis—Fluorouracil—skin cancer	0.000162	0.0011	CcSEcCtD
Nabumetone—Decreased appetite—Docetaxel—skin cancer	0.000161	0.00109	CcSEcCtD
Nabumetone—Headache—Fluorouracil—skin cancer	0.000161	0.00109	CcSEcCtD
Nabumetone—Fatigue—Docetaxel—skin cancer	0.00016	0.00108	CcSEcCtD
Nabumetone—Constipation—Docetaxel—skin cancer	0.000159	0.00107	CcSEcCtD
Nabumetone—Feeling abnormal—Docetaxel—skin cancer	0.000153	0.00103	CcSEcCtD
Nabumetone—Nausea—Fluorouracil—skin cancer	0.000153	0.00103	CcSEcCtD
Nabumetone—Gastrointestinal pain—Docetaxel—skin cancer	0.000152	0.00103	CcSEcCtD
Nabumetone—Body temperature increased—Docetaxel—skin cancer	0.000147	0.000993	CcSEcCtD
Nabumetone—Abdominal pain—Docetaxel—skin cancer	0.000147	0.000993	CcSEcCtD
Nabumetone—Hypersensitivity—Docetaxel—skin cancer	0.000137	0.000925	CcSEcCtD
Nabumetone—Asthenia—Docetaxel—skin cancer	0.000133	0.000901	CcSEcCtD
Nabumetone—Pruritus—Docetaxel—skin cancer	0.000131	0.000888	CcSEcCtD
Nabumetone—Diarrhoea—Docetaxel—skin cancer	0.000127	0.000859	CcSEcCtD
Nabumetone—Dizziness—Docetaxel—skin cancer	0.000123	0.00083	CcSEcCtD
Nabumetone—Vomiting—Docetaxel—skin cancer	0.000118	0.000798	CcSEcCtD
Nabumetone—Rash—Docetaxel—skin cancer	0.000117	0.000792	CcSEcCtD
Nabumetone—Dermatitis—Docetaxel—skin cancer	0.000117	0.000791	CcSEcCtD
Nabumetone—Headache—Docetaxel—skin cancer	0.000116	0.000787	CcSEcCtD
Nabumetone—Nausea—Docetaxel—skin cancer	0.00011	0.000746	CcSEcCtD
